Bruno Marchou - Infectious Diseases

Author Information

Bruno Marchou is affiliated with the Department of Infectious and Tropical Diseases at Toulouse University Hospital, located in Toulouse, France. He is also connected with the Paul Sabatier Toulouse III University and actively involved in research at the Inserm U1043 - CNRS UMR 5282, Toulouse-Purpan Pathophysiology Center. His work primarily focuses on infectious diseases, and he is recognized for his contributions to the field through his research and publications.

Research Contributions

Bruno Marchou has made significant contributions to the study of infectious diseases, with a particular focus on HIV and Hepatitis C virus (HCV) coinfections, as well as the implications of cannabis use in these populations. His research includes studies on the efficacy of antiviral treatments, the impact of cannabis on plasma HIV RNA levels, and the evaluation of biomarkers in HIV-related lymphomas. Marchou's work often involves data from the ANRS CO13 HEPAVIH cohort, highlighting his commitment to understanding and improving the health outcomes of individuals living with HIV and HCV.

Aliases

Bruno Marchou is also known by the aliases B Marchou and B. Marchou. These variations are often used in academic publications and references.

Publication and Citation Metrics

Metric	Value
Citation Count	4903
H-index	39
Paper Count	163

Publications:

HCV cure: an appropriate moment to reduce cannabis use in people living with HIV? (ANRS CO13 HEPAVIH data)

DOI: 10.1186/s12981-022-00440-9

Year: 2022

Prospective evaluation of blood Epstein Barr virus DNA load and antibody profile in HIV-related non-Hodgkin lymphomas.

DOI: 10.1097/QAD.0000000000002839

Year: 2021

Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH).

DOI: 10.1016/j.jhep.2019.10.019

Year: 2020

Hematogenous osteomyelitis in childhood can relapse many years later into adulthood

DOI: 10.1097/MD.0000000000019617

Year: 2020

Cannabis Use and Plasma Human Immunodeficiency Virus (HIV) RNA Levels in Patients Coinfected With HIV and Hepatitis C Virus Receiving Antiretroviral Therapy: Data From the ANRS CO13 HEPAVIH Cohort

DOI: 10.1093/CID/CIAA117

Year: 2020

False-negative Results of Human Immunodeficiency Virus (HIV) Rapid Testing in HIV Controllers.

DOI: 10.1093/cid/ciz734

Year: 2019

Efficacy of teicoplanin monotherapy following initial standard therapy in Enterococcus faecalis infective endocarditis: a retrospective cohort study

DOI: 10.1007/s15010-019-01290-w

Year: 2019

Olecranon bursitis secondary to Mycobacterium europaeum infection in a patient receiving immunosuppressive drugs for rheumatoid arthritis.

DOI: 10.1016/j.medmal.2019.03.002

Year: 2019

Epstein-Barr virus biomarkers have no prognostic value in HIV-related Hodgkin lymphoma in the modern cART era.

DOI: 10.1097/QAD.0000000000002129

Year: 2019

HCV-Related Mortality Among HIV/HCV Co-infected Patients: The Importance of Behaviors in the HCV Cure Era (ANRS CO13 HEPAVIH Cohort)

DOI: 10.1007/s10461-019-02585-7

Year: 2019

What are Direct Acting Antivirals (DAAs)?

How Do Pathogens Enter the Host?

What Are the Consequences?

What Are the Challenges in Targeting the Apicoplast?

What are the key components of good hygiene?

What Diseases Does DTaP Protect Against?

How Do Fungal Pathogens Affect Us?

What are the Symptoms of Herpes?

What Role Do Host Proteins Play?

Can Glycolysis Be a Therapeutic Target?

Partnered Content Networks

Relevant Topics